The pharmaceutical industry is a complex web of interests, and the recent report by the Grattan Institute has shed light on a concerning trend: the Pharmacy Guild of Australia's stranglehold on the market, potentially hindering access to affordable medicines for Australians. This is not just a story about lobbying and politics; it's about the very real impact on patients and the future of healthcare in the country.
The Power of the Pharmacy Guild
In my opinion, the Pharmacy Guild's influence is a critical issue that demands attention. The guild's role as the biggest donor in the health industry gives it significant political clout, and this power is being wielded to shape policies that affect every Australian. The 'Community Pharmacy Agreements' are a prime example of this. These agreements, negotiated behind closed doors, secure almost $4 billion annually for pharmacy services, yet they lack external scrutiny and transparency. This is a recipe for disaster, as it allows the guild to dictate terms that may not be in the best interest of patients.
The guild's claim that these agreements are essential for pharmacies is debatable. Peter Breadon, the Grattan's health director, argues that the terms are 'generous' and protect pharmacy owners from revenue declines. However, what many people don't realize is that this generosity may come at the expense of patients. The guild's survey of its members suggests increased profits, but the question remains: at what cost?
Dispensing Fees and Unjustified Charges
One of the most concerning aspects of the report is the dispensing fees. The fee for receiving a script, verifying it, and preparing the medicine is about $9 for an average medicine. However, the Grattan report reveals that these fees are not based on the actual cost of dispensing, and there's no way to know the real cost. This is a classic example of how the guild's influence can lead to unjustified charges for patients. The report suggests that taxpayers may be overpaying, and this is a serious concern.
The 'allowable additional patient charge' of $2.80 on some medicines is another example of how pharmacies can exploit patients. This fee doesn't compensate for service, and it's unjustified. The report calls for the removal of these fees, stating that they should be scrapped. The $1 discount that has been available over the last decade, which saved patients about $48 million in 2022-23, is also under threat. This discount, in my view, is a small but significant step towards making medicines more affordable, and its end by 2029 is a cause for concern.
Location Rules and Competition
The Pharmacy Guild's influence extends to location rules, which stifle competition. The rule that new pharmacies must be at least 10 kilometers from another one is a barrier to entry for new players. This, in turn, limits the number of pharmacies in vulnerable communities. The guild argues that this ensures pharmacies don't just open in commercially attractive locations, but in my perspective, it's a way to maintain control and protect existing pharmacies from competition. Other countries have scrapped these rules, and the result is often more pharmacies, longer opening hours, and lower prices.
The Way Forward
The Grattan report recommends abolishing the Community Pharmacy Agreements by 2029, when the current agreement expires. This is a bold move that could potentially disrupt the status quo. If the government doesn't take this step, the report suggests including pharmacists and patients in negotiations and having the Independent Health and Aged Care Pricing Authority set funding rates. This, in my opinion, is a more transparent and patient-centric approach.
In conclusion, the Pharmacy Guild's influence on the pharmaceutical market is a complex issue with far-reaching implications. It's a story of power, politics, and patients. As an expert, I believe that the future of healthcare in Australia depends on addressing these concerns and finding a balance between the interests of the guild and the needs of patients. The time for change is now, and the Grattan report provides a compelling case for action.
